Xbrane Biopharma Revenue and Competitors

Solna,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Xbrane Biopharma's estimated annual revenue is currently $19.2M per year.(i)
  • Xbrane Biopharma's estimated revenue per employee is $155,000

Employee Data

  • Xbrane Biopharma has 124 Employees.(i)
  • Xbrane Biopharma grew their employee count by 39% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.

keywords:N/A

N/A

Total Funding

124

Number of Employees

$19.2M

Revenue (est)

39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Xbrane Biopharma News

2022-04-20 - Do Institutions Own Xbrane Biopharma AB (publ) (STO:XBRANE) Shares?

Xbrane Biopharma is not a large company by global standards. It has a market capitalization of kr2.2b, which means it wouldn't have the...

2022-04-17 - Triptorelin Drug Market Size 2022-2029| Key Players ...

Debiopharm Group; Ipsen; Xbrane Biopharma; Chengdu Tiantaishan Pharmaceutical; Arbor Pharmaceuticals; Ferring. Triptorelin Drug Market Breakdown by Type: 3.75...

2022-04-17 - Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$36M12453%N/A
#2
$15.1M12656%N/A
#3
$15.1M12656%N/A
#4
$15.1M12656%N/A
#5
$26.7M12751%N/A